Transcutaneous Peripheral Nerve Stimulation for Essential Tremor: Advancements from a 2024 Randomized Clinical Trial and Evolving Evidence
Highlights
- An AI-driven transcutaneous peripheral nerve stimulation (TPNS) device significantly improved activities of daily living (mADL scores) related to upper limb tremor in ET at 90 days compared to sham.
- Evidence synthesis from clinical trials shows peripheral nerve stimulation (PNS) can modulate tremor amplitude and severity, offering a safe and noninvasive therapeutic option.
- Real-time AI adjustment of stimulation parameters targeting radial, median, and ulnar nerves enhances the neuromodulation precision and clinical benefit.
- Adverse events are generally mild, with skin irritation most common; longer-term safety and efficacy require further evaluation.
Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.